Back to Search Start Over

당뇨병에서 지속되는 비만에 대한 장기간 사용 가능한 약물요법.

Authors :
김종화
Source :
Journal of Korean Diabetes. Mar2020, Vol. 21 Issue 1, p21-26. 6p.
Publication Year :
2020

Abstract

Obesity increases the risk of diabetes, hypertension, and cardiovascular diseases, ultimately contributing to mortality. The Korean Society for the Study of Obesity (KSSO) was established to improve the management of obesity through research and education; to that end, the Committee of Clinical Practice Guidelines of the KSSO reviews systemic evidence using expert panels to develop clinical guidelines. Weight-loss medications are effective adjuncts to diet, physical activity, and behavioral counseling for select Korean patients with type 2 diabetes and body mass index ≥ 25 kg/m². Potential benefits must be weighed against the potential risks of these medications. If a patient's response to weight-loss medications is < 5% weight loss after 3 months or if there are significant safety or tolerability issues at any time, the medication should be discontinued and alternative medications or treatment approaches should be considered. Long-term medications for enduring obesity have traditionally fallen into two major categories, centrally-acting anorexiant medications and peripherally acting medications, such as orlistat. In this paper, I provide the definition of obesity in Korea and describe anti-obesity medications currently available for long-term treatment in diabetes. [ABSTRACT FROM AUTHOR]

Details

Language :
Korean
ISSN :
22337431
Volume :
21
Issue :
1
Database :
Academic Search Index
Journal :
Journal of Korean Diabetes
Publication Type :
Academic Journal
Accession number :
147892875
Full Text :
https://doi.org/10.4093/jkd.2020.21.1.21